Search This Blog

Friday, June 27, 2025

BioCryst to sell European ORLADEYO business to Neopharmed for $264M

 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has entered into an agreement to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million, according to a press release statement issued Friday.

The deal includes a $250 million upfront payment and potential future milestone payments of up to $14 million related to sales in Central and Eastern Europe. BioCryst plans to use the proceeds to retire its remaining term debt of $249 million from Pharmakon, eliminating approximately $70 million in future interest payments. The company’s current total debt stands at $829 million, with a current ratio of 2.93x indicating strong short-term liquidity position.

As part of the transaction, Neopharmed Gentili will acquire BioCryst’s European organization, which is expected to result in at least $50 million in annual operating expense savings for BioCryst. The Italian pharmaceutical company will also assume responsibility for all royalties related to European sales.

BioCryst now forecasts it will end 2027 with approximately $700 million in cash and no term debt, representing a $400 million increase from its previous guidance. 

"This transaction is consistent with our strategy of making ORLADEYO available to patients in Europe through the team we built, and it now provides the capital to retire our remaining term debt," said Jon Stonehouse, president and chief executive officer of BioCryst.

https://www.investing.com/news/company-news/biocryst-to-sell-european-orladeyo-business-to-neopharmed-for-264m-93CH-4114313

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.